WVE Stock Forecast & Price Target

Wave Life Sciences is viewed favorably because its PRISM platform is generating differentiated value across multiple modalities, including RNA editing, antisense silencing, and RNA interference, with preclinical data showing standout tissue targeting and bifunctional constructs that outperform stand-alone components. The clearest near-term catalyst is WVE-006 in AATD, where FDA alignment on a single two-year registrational trial with a one-year biomarker interim and supportive 600 mg data could validate an FDA-aligned path, while the program’s biomarker results already show functional M-AAT gains to 59%-64% and Z-AAT reductions of 68%-71%. WVE also has a meaningful obesity opportunity in WVE-007, with 3Q26 cash and investments of about $431.0M supporting runway into 3Q28 and a broad catalyst set around 4Q26, 2027, and beyond that could unlock underappreciated platform value.

Wave Life Sciences is viewed negatively because its pipeline still faces substantial clinical uncertainty, with safety or efficacy setbacks in programs like WVE-003, WVE-N531, and WVE-006 likely to undermine development prospects. The company also faces an unclear regulatory pathway, possible FDA disagreement on filing standards, and no guarantee of approval or reimbursement, while commercialization looks difficult given intense competition in HD, DMD, and AATD and uncertain market potential. Financially, it is expected to need additional capital before profitability, and any raise on unfavorable terms could dilute shareholders and constrain execution of its growth plans.